Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 3
2012 2
2015 9
2016 15
2017 9
2018 8
2019 17
2020 11
2021 13
2022 11
2023 9
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Results by year

Filters applied: . Clear all
Page 1
A phase II open-label randomized clinical trial of preoperative durvalumab or durvalumab plus tremelimumab in resectable head and neck squamous cell carcinoma.
Kim CG, Hong MH, Kim D, Lee BH, Kim H, Ock CY, Kelly G, Bang YJ, Kim G, Lee JE, Kim C, Kim SH, Hong HJ, Park YM, Sim NS, Park H, Park JW, Lee CG, Kim KH, Park G, Jung I, Han D, Kim JH, Cha J, Lee I, Kang M, Song H, Oum C, Kim S, Kim S, Lim Y, Kim-Schulze S, Merad M, Yoon SO, Kim HJ, Koh YW, Kim HR. Kim CG, et al. Among authors: ock cy. Clin Cancer Res. 2024 Mar 8. doi: 10.1158/1078-0432.CCR-23-3249. Online ahead of print. Clin Cancer Res. 2024. PMID: 38457288
Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types.
Shen J, Choi YL, Lee T, Kim H, Chae YK, Dulken BW, Bogdan S, Huang M, Fisher GA, Park S, Lee SH, Hwang JE, Chung JH, Kim L, Song H, Pereira S, Shin S, Lim Y, Ahn CH, Kim S, Oum C, Kim S, Park G, Song S, Jung W, Kim S, Bang YJ, Mok TSK, Ali SM, Ock CY. Shen J, et al. Among authors: ock cy. J Immunother Cancer. 2024 Feb 14;12(2):e008339. doi: 10.1136/jitc-2023-008339. J Immunother Cancer. 2024. PMID: 38355279 Free PMC article.
Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04).
Park S, Kim TM, Han JY, Lee GW, Shim BY, Lee YG, Kim SW, Kim IH, Lee S, Kim YJ, Park JH, Park SG, Lee KH, Kang EJ, Kim JW, Shin SH, Ock CY, Nam BH, Lee J, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ. Park S, et al. Among authors: ock cy. J Clin Oncol. 2024 Apr 10;42(11):1241-1251. doi: 10.1200/JCO.23.01891. Epub 2023 Oct 20. J Clin Oncol. 2024. PMID: 37861993 Clinical Trial.
Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a predictive biomarker for axitinib in adenoid cystic carcinoma.
Kim DH, Lim Y, Ock CY, Park G, Park S, Song H, Ma M, Mostafavi M, Kang EJ, Ahn MJ, Lee KW, Kwon JH, Yang Y, Choi YH, Kim MK, Ji JH, Yun T, Kim SB, Keam B. Kim DH, et al. Among authors: ock cy. Head Neck. 2023 Dec;45(12):3086-3095. doi: 10.1002/hed.27537. Epub 2023 Oct 13. Head Neck. 2023. PMID: 37828867 Clinical Trial.
Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a biomarker in locally advanced unresectable thymic epithelial neoplasm: A single-center, retrospective, longitudinal cohort study.
Kim DH, Lim Y, Kim S, Ock CY, Youk J, Kim M, Kim TM, Kim DW, Kim HJ, Koh J, Jung KC, Na KJ, Kang CH, Keam B. Kim DH, et al. Among authors: ock cy. Thorac Cancer. 2023 Oct;14(30):3001-3011. doi: 10.1111/1759-7714.15089. Epub 2023 Sep 7. Thorac Cancer. 2023. PMID: 37675597 Free PMC article.
92 results